Pharmaceutics, 2021, 13(9)

Amphiphilic Poly(N-vinylpyrrolidone) Nanoparticles Conjugated with DR5-Specific Antitumor Cytokine DR5-B for Targeted Delivery to Cancer Cells

Nanoparticles based on the biocompatible amphiphilic poly(N-vinylpyrrolidone) (Amph-PVP) derivatives are promising for drug delivery. Amph-PVPs self-aggregate in aqueous solutions with the formation of micellar nanoscaled structures. Amph-PVP nanoparticles are able to immobilize therapeutic molecules under mild conditions. As is well known, many efforts have been made to exploit the DR5-dependent apoptosis induction for cancer treatment. The aim of the study was to fabricate Amph-PVP-based nanoparticles covalently conjugated with antitumor DR5-specific TRAIL (Tumor necrosis factor-related apoptosis-inducing ligand) variant DR5-B and to evaluate their in vitro cytotoxicity in 3D tumor spheroids. The Amph-PVP nanoparticles were obtained from a 1:1 mixture of unmodified and maleimide-modified polymeric chains, while DR5-B protein was modified by cysteine residue at the N-end for covalent conjugation with Amph-PVP. The nanoparticles were found to enhance cytotoxicity effects compared to those of free DR5-B in both 2D (monolayer culture) and 3D (tumor spheroids) in vitro models. The cytotoxicity of the nanoparticles was investigated in human cell lines, namely breast adenocarcinoma MCF-7 and colorectal carcinomas HCT116 and HT29. Notably, DR5-B conjugation with Amph-PVP nanoparticles sensitized resistant multicellular tumor spheroids from MCF-7 and HT29 cells. Taking into account the nanoparticles loading ability with a wide range of low-molecular-weight antitumor chemotherapeutics into hydrophobic core and feasibility of conjugation with hydrophilic therapeutic molecules by click chemistry, we suggest further development to obtain a versatile system for targeted drug delivery into tumor cells.

IBCH: 9444
Ссылка на статью в журнале: https://www.mdpi.com/1999-4923/13/9/1413
Кол-во цитирований на 05.2024: 7
Данные статьи проверены модераторами 2021-09-27

Список научных проектов, где отмечена публикация

  1. Разработка таргетных противоопухолевых препаратов на основе рецептор-селективного варианта цитокина TRAIL, включенного в наноносители (21 Марта 2018 года — 9 Апреля 2020 года). Яголович А.В.. Грант, РФФИ.
  2. Новые мультитаргетные гибридные белки на основе высокоспецифичного мутантного варианта цитокина TRAIL DR5-B с эффекторными пептидами для параллельного воздействия на различные сигнальные пути, влияющие на развитие опухолей (26 Апреля 2021 года — 31 Декабря 2023 года). Долгих Д.А., Гаспарян М.Э., Марквичева Е.А., Яголович А.В., Артыков А.А., Воронцова Е.В., Гилёва А.М., Исакова А.А., Рыбченко В.С., Черткова Р.В.. Грант, РНФ.